A Phase 1 interventional study of VIR-3434 and Placebo in Chronic Hepatitis B, sponsored by Vir Biotechnology, Inc.. Completed at 24 sites in 7 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by Vir Biotechnology, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Hepatitis B, Chronic with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · Germany.
Among the 53 studies in Hepatitis B, Chronic with a site in Germany, this one is the 25th largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2020, is one of 6 in phase 1, and was the 40th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 53 studies in Hepatitis B, Chronic with a site in Germany is open now. Recruiting first, the newest first:
Michael Hoelscher · Sites in Germany
Ages 18–70
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 16 · Phase 3 14 · Phase 4 7
First in 2002; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 137 across the 44 interventional studies, 331 across the 9 observational. Of the 46 that completed or were terminated, 28 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 53 have an industry lead sponsor. The 10 most frequent:
Vir Biotechnology, Inc. is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Vir Biotechnology, Inc. has 5 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
2 of the studies in Hepatitis B, Chronic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06513286Michael HoelscherTherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate | 2026-12 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Hepatitis B, Chronic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1 study in which healthy volunteers and participants with chronic HBV infection will receive VIR-3434 or placebo and will be assessed for safety, tolerability, pharmacokinetics (PK), and antiviral activity (only in participants with chronic HBV infection).
Healthy Volunteers:
Inclusion Criteria:
Exclusion Criteria:
CHB Patients:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: VIR-3434
Other: Placebo
VIR-3434 given by subcutaneous injection or intravenous infusion.
Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Treatment-emergent period, which is up to Week 24 in part A, and up to Week 8 in part B/C/D
Number of Participants With Clinical Laboratory Abnormalities
Time frame: Up to 280 days post-dose
Cmax
VIR-3434 Maximum Concentration in Serum
Time frame: Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Tmax
VIR-3434 time of Cmax in Serum
Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
AUClast
VIR-3434 under the curve from time 0 to last measurable Time
Time frame: Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
t1/2
VIR-3434 apparent Elimination Half-life (t1/2) in serum
Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Vz/F
VIR-3434 Volume of Distribution (SC only)
Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Vz
VIR-3434 Volume of Distribution (IV only)
Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose
CL/F
VIR-3434 Apparent serum clearance (SC only)
Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose; Parts B-D: pre-dose and 1, 4, 6, 24 hours, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
CL
VIR-3434 Apparent serum clearance (IV only)
Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose
Number of Participants With ADA to VIR-3434
Evaluate the immunogenicity of VIR-3434
Time frame: Part A: Up to 168 days post-dose. Parts B-D: Up to 280 days post-dose
Maximum Reduction of Serum HBsAg From Baseline (Day 1 Predose)
HBsAg reductions at nadir and Week 4
Time frame: Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Part D Only: Maximum Change of HBV DNA From Baseline (Day 1 Predose)
HBV DNA reductions at nadir and Week 4
Time frame: Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose Parts B-D: pre-dose and 1, 3, 7, 10, 14, 28, 56, 84, 112, 168, 224, 280 days post-dose
Titers (if Applicable) of ADA to VIR-3434
Evaluate the immunogenicity of VIR-3434
Time frame: Part A: Up to 168 days post-dose. Parts B-D: Up to 280 days post-dose
Cmax
VIR-3434 Maximum Concentration in Serum
Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose
AUClast
VIR-3434 under the curve from time 0 to last measurable Time
Time frame: Part A: pre-dose and 1, 4, 6, 24 hours, 3, 7, 14, 28, 56, 84, 126, 168 days post-dose
| Milestone | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 11 | 6 | 6 | 6 | 6 | 8 | 6 | 6 | 6 | 6 | 6 | 6 | 4 |
| Entered extended follow up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 5 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 |
| Completed | 6 | 6 | 6 | 6 | 6 | 10 | 6 | 6 | 6 | 6 | 8 | 6 | 6 | 4 | 6 | 6 | 6 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Participants | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 5 | 4 | 5 | 4 | 3 | 6 | 2 | 4 | 3 | 3 | 2 | 2 | 4 | 5 | 4 | 2 | 6 | 3 |
| Participants | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT Grade 1 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 5 | 0 |
| ALT Grade 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase Grade 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Grade 1 | 0 | 0 | 1 | 0 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| AST Grade 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin Grade 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin Grade 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VIR-3434 Maximum Concentration in Serum
| Parts B-D: ng/mL | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|
| Cmax | 352 ± 27.0 | 456 ± 152.8 | 5460 ± 36.5 | 19700 ± 56.9 | 835 ± NA | 4750 ± 46.9 | 26100 ± 21.8 | 6000 ± 16.8 | 10800 ± 61.4 |
VIR-3434 time of Cmax in Serum
| day | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax | 7.00 (3.00 to 7.01) | 7 (3 to 7.00) | 3 (3.00 to 7.00) | .0833 (0.0417 to 0.292) | .0833 (0.0417 to 0.0847) | 6.90 (1.01 to 7.00) | 2.92 (1.00 to 6.88) | 5.44 (2.83 to 7.03) | 2.96 (2.11 to 6.97) | 3.98 (3.98 to 3.98) | 3.00 (2.95 to 3.94) | 2.99 (2.86 to 6.97) | 4.08 (0.0417 to 8.11) | 2.99 (2.91 to 3.15) |
VIR-3434 under the curve from time 0 to last measurable Time
| Parts B-D: day*ng/mL | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|
| AUClast | 3130 ± 67.5 | 4150 ± 270.0 | 106000 ± 72.3 | 381000 ± 94.2 | 9540 ± NA | 39000 ± 133.0 | 181,000 ± 964.4 | 9,270 ± 1,139.9 | 54,300 ± 122.7 |
VIR-3434 apparent Elimination Half-life (t1/2) in serum
| day | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| t1/2 | 28.5 (27.0 to 30.3) | 24.3 (23.2 to 26.6) | 25.2 (21.6 to 28.7) | 24.0 (20.7 to 25.7) | 20.7 (19.3 to 22.7) | 3.57 (2.33 to 4.81) | 6.34 (6.34 to 6.34) | 7.94 (3.54 to 17.2) | 13.6 (5.96 to 16.0) | 3.82 (3.82 to 3.82) | 4.25 (2.48 to 6.02) | 8.36 (4.16 to 11.8) | 3.17 (3.17 to 3.17) | 1.99 (1.99 to 1.99) |
VIR-3434 Volume of Distribution (SC only)
| mL | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vz/F | 12200 ± 15.2 | 10900 ± 27.3 | 10600 ± 27.7 | 9420 ± 12.9 | 4540 ± NA | 7410 ± 21.5 | 9830 ± 54.2 | 10300 ± NA | 6710 ± 27.4 | 7330 ± 22.5 | 5000 ± NA | 4880 ± NA |
VIR-3434 Volume of Distribution (IV only)
| mL | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV |
|---|---|---|
| Vz | 7620 ± 26.3 | 7290 ± 24.6 |
VIR-3434 Apparent serum clearance (SC only)
| mL/day | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CL/F | 295 ± 16.0 | 308 ± 22.7 | 292 ± 19.7 | 1950 ± 71.2 | 496 ± NA | 697 ± 71.6 | 653 ± 85.6 | 1860 ± NA | 1200 ± 111.2 | 670 ± 32.8 | 1090 ± NA | 1700 ± NA |
VIR-3434 Apparent serum clearance (IV only)
| mL/day | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV |
|---|---|---|
| CL | 244 ± 19.6 | 1950 ± 71.2 |
Evaluate the immunogenicity of VIR-3434
| Participants | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With ADA to VIR-3434 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 2 | 4 | 1 |
HBsAg reductions at nadir and Week 4
| IU/mL | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nadir | -1.30 ± 0.152 | -1.27 ± 0.666 | -1.96 ± 0.436 | -2.24 ± 0.353 | -0.04 ± 0.039 | -1.05 ± 0.598 | -1.28 ± 0.749 | -2.17 ± 0.252 | -0.06 ± 0.092 | -1.77 ± 0.931 | -1.83 ± 0.219 | -0.09 ± 0.039 |
| Week 4 | -0.61 ± 0.400 | -0.38 ± 0.503 | -1.51 ± 0.245 | -1.69 ± 0.766 | 0.02 ± 0.039 | -0.30 ± 0.382 | -0.16 ± 0.175 | -1.43 ± 0.711 | -0.01 ± 0.129 | -0.48 ± 0.608 | -0.37 ± 0.368 | -0.00 ± 0.016 |
HBV DNA reductions at nadir and Week 4
| IU/mL | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo |
|---|---|---|---|
| Nadir | -1.44 ± 0.998 | -2.07 ± 1.007 | -0.12 ± 0.06 |
| Week 4 | -0.70 ± 0.917 | -0.61 ± 1.195 | 0.06 ± 0.472 |
Evaluate the immunogenicity of VIR-3434
| Median Titer | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Titers (if Applicable) of ADA to VIR-3434 | 0 (0 to 0) | 20 (20 to 40) | 160 (160 to 160) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 40 (40 to 40) | 80 (40 to 160) | 240 (20 to 1280) | 120 (80 to 160) | 80 (80 to 80) | 20 (19 to 40) | 40 (20 to 2560) | 20 (20 to 320) |
VIR-3434 Maximum Concentration in Serum
| Part A: μg/mL | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV |
|---|---|---|---|---|---|
| Cmax | 9.46 ± 27.4 | 32.1 ± 18.0 | 105 ± 23.7 | 363 ± 32.6 | 1060 ± 20.00 |
VIR-3434 under the curve from time 0 to last measurable Time
| Part A: day*µg/mL | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV |
|---|---|---|---|---|---|
| AUClast | 302 ± 16.0 | 964 ± 22.6 | 3060 ± 19.8 | 4010 ± 28.5 | 12300 ± 19.7 |
Collected over Treatment-emergent period, which is up to Week 24 in part A, and up to Week 8 in part B/C/D. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Healthy Participants 90 mg SC | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A Healthy Participants 300 mg SC | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A Healthy Participants 900 mg SC | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part A Healthy Participants 900 mg IV | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A: Healthy Participants 3000 mg IV | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A Healthy Participants Placebo | 0/11 (0%) | 0/11 (0%) | 6/11 (54.5%) |
| Part B: HBV Participants 6 mg SC | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part B: HBV Participants 18 mg SC | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part B: HBV Participants 75 mg SC | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part B: HBV Participants 300 mg SC | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part B: HBV Participants Placebo | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Part C: HBV Participants 18 mg SC | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part C: HBV Participants 75 mg SC | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part C: HBV Participants 300 mg SC | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Part C: HBV Participants Placebo | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part D: HBV Participants 75 mg SC | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part D: HBV Participants 300 mg SC | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part D: HBV Participants Placebo | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Event | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anaphylactic ReactionImmune system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/4 |
| Event | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/6 | 3/6 | 1/6 | 1/6 | 1/6 | 2/11 | 0/6 | 0/6 | 1/6 | 2/6 | 2/8 | 0/6 | 0/6 | 4/6 | 0/6 | 1/6 | 3/6 | 1/4 |
| ChillsGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 0/6 | 4/6 | 0/6 | 0/6 | 1/6 | 0/4 |
| Injection site erythemaGeneral disorders | 0/6 | 3/6 | 1/6 | 0/6 | 0/6 | 0/11 | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 1/6 | 2/6 | 0/6 | 3/6 | 0/4 |
| FatigueGeneral disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/11 | 0/6 | 0/6 | 1/6 | 0/6 | 0/8 | 0/6 | 0/6 | 1/6 | 3/6 | 0/6 | 1/6 | 0/4 |
| NauseaGastrointestinal disorders | 1/6 | 1/6 | 0/6 | 0/6 | 2/6 | 2/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 0/6 | 1/6 | 1/6 | 0/6 | 0/4 |
| DizzinessNervous system disorders | 0/6 | 0/6 | 0/6 | 2/6 | 1/6 | 0/11 | 0/6 | 1/6 | 0/6 | 0/6 | 0/8 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 0/6 | 1/4 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/6 | 0/6 | 1/6 | 2/6 | 0/6 | 1/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/4 |
| Injection Site PainGeneral disorders | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 1/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/4 |
| PyrexiaGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/11 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/4 |
| Age, Continuous(years) | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 31.3 ± 11.94 | 27.7 ± 7.92 | 31.5 ± 9.77 | 24.8 ± 4.58 | 29.3 ± 12.99 | 30.3 ± 10.77 | 56.3 ± 5.72 | 49.0 ± 6.93 | 50.8 ± 8.35 | 50.0 ± 8.81 | 51.6 ± 6.35 | 44.5 ± 10.82 | 38.2 ± 8.33 | 38.8 ± 8.95 | 44.0 ± 8.53 | 42.7 ± 7.71 | 38.0 ± 6.16 | 37.3 ± 8.54 | 39.6 ± 12.37 |
| Sex: Female, Male(Participants) | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 4 | 5 | 4 | 6 | 0 | 0 | 2 | 1 | 1 | 3 | 2 | 2 | 3 | 4 | 3 | 2 | 49 |
| Male | 2 | 3 | 2 | 1 | 2 | 5 | 6 | 6 | 4 | 5 | 7 | 3 | 4 | 4 | 3 | 2 | 3 | 2 | 64 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Not Hispanic or Latino | 5 | 6 | 4 | 5 | 6 | 9 | 5 | 3 | 5 | 6 | 6 | 6 | 5 | 5 | 5 | 6 | 6 | 4 | 97 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 1 | 0 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 12 |
| Race (NIH/OMB)(Participants) | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 2 | 4 | 4 | 6 | 5 | 0 | 0 | 3 | 5 | 2 | 0 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 6 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 6 |
| White | 3 | 3 | 3 | 4 | 2 | 7 | 3 | 3 | 2 | 1 | 1 | 1 | 5 | 6 | 2 | 0 | 3 | 2 | 51 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 3 | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 14 |
| Baseline HbsAg (IU/mL)(log 10 IU/mL) | Part A: Healthy Participants 90 mg SC | Part A Healthy Participants 300 mg SC | Part A Healthy Participants 900 mg SC | Part A Healthy Participants 900 mg IV | Part A: Healthy Participants 3000 mg IV | Part A Healthy Participants Placebo | Part B: HBV Participants 6 mg SC | Part B: HBV Participants 18 mg SC | Part B: HBV Participants 75 mg SC | Part B: HBV Participants 300 mg SC | Part B: HBV Participants Placebo | Part C: HBV Participants 18 mg SC | Part C: HBV Participants 75 mg SC | Part C: HBV Participants 300 mg SC | Part C: HBV Participants Placebo | Part D: HBV Participants 75 mg SC | Part D: HBV Participants 300 mg SC | Part D: HBV Participants Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | — | — | 1.94 ± 0.617 | 2.78 ± 0.711 | 2.55 ± 0.693 | 2.59 ± 1.150 | 2.24 ± 0.638 | 3.34 ± 0.455 | 4.12 ± 0.353 | 3.71 ± 0.375 | 3.18 ± 1.652 | 3.79 ± 0.729 | 4.29 ± 0.305 | 4.15 ± 0.496 | 3.17 ± 1.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2020 to primary completion in Oct 2022, 28 months.
Results were first posted in Oct 2024, 1 year 11 months after primary completion.
Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 28 months is above that.
Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tobevibart